The funding will support clinical testing of NovaResp’s cMAP software, which aims to provide personalized, low-pressure CPAP by predicting apnea events during sleep.


Summary: NovaResp Technologies Inc has raised $3 million in a seed extension round to support clinical testing of its cMAP positive airway pressure (PAP) software. The round was led by Neil Smith, MD, and included key investors such as Invest Nova Scotia and Concrete Ventures. NovaResp’s cMAP software uses artificial intelligence to deliver personalized, low-pressure CPAP therapy.

Key Takeaways:

  • NovaResp secured $3 million to advance the clinical testing of its innovative cMAP CPAP therapy software.
  • The cMAP software uses artificial intelligence and machine learning to predict and prevent sleep apnea episodes, which the company hopes will provide more comfortable and effective low-pressure therapy.
  • Led by Neil Smith, MD, and supported by major investors, the funding round reflects strong belief in the potential of NovaResp’s technology to revolutionize sleep apnea treatment.

NovaResp Technologies Inc has raised a $3 million seed extension round to support clinical testing of its cMAP positive airway pressure software. 

The round was led by Neil Smith, MD, an otolaryngologist and company board member, who was joined by fellow board member Raj Sodhi, MBA, and the previous lead investors of NovaResp’s seed preferred round, Invest Nova Scotia and Concrete Ventures. The financing also included participation from the Ontario-based Centre for Aging + Brain Health Innovation and various new and existing investors.

“It is incredible how well our round was received. We have a dynamic group of new and existing investors who share our vision of revolutionizing CPAP treatment and patient adherence through personalized, low-pressure therapy for those suffering from sleep apnea and other respiratory conditions,” says Hamed Hanafi, founder and CEO of NovaResp, in a release. “Our board and investors strongly believe in the potential of cMAP, and they demonstrated that by the speed in which the round was fully subscribed.” 

cMAP, Nova Resp’s primary software product, uses artificial intelligence and machine learning during PAP therapy to predict and prevent sleep apnea episodes before they occur. As a result, personalized therapy can be delivered via PAP machines at lower, more comfortable air pressure levels, leading to improved patient adherence and better outcomes, according to the company. cMAP is an investigational technology still under development and has not been cleared by the US Food and Drug Administration.

Belief in cMAP Software Drive Funding Round

Smith, who led the round, was a founder of the Snore Shop and CEO of Resolute Health Corp Ltd when it was acquired by The Kensington Private Equity Fund in 2022. “I’m a real believer in NovaResp and its cMAP software,” he says in a release. “Lower pressure CPAP therapy is the future, so when the company decided to raise money, I offered to lead the round. I told Hamed I wanted to help the company get the software to patients as quickly as possible. My offer to lead was, in part, to help the company spend less time fundraising and more time perfecting their algorithm.” 

Sodhi adds in a release, “Acclimating and adhering to PAP therapy is difficult for many patients. cMAP offers a significant improvement to the core device algorithm and promises to increase the likelihood of short- and long-term patient success on therapy and reduce the total labor for those supporting the patient.” 

Photo 40380725 © Abdullatif Omar | Dreamstime.com